Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Boehringer Slates Biologics In China
by Michael McCoy
June 17, 2013
| A version of this story appeared in
Volume 91, Issue 24
Boehringer Ingelheim has teamed up with China’s Zhangjiang Biotech & Pharmaceutical Base Development Co. for what it says will be the first plant for drugs based on mammalian cell cultures to be built in China by an international firm. In addition to being a drug company in its own right, Boehringer is a major contract manufacturer of biologic drugs. The German firm says the new plant, to cost more than $45 million, will provide development and clinical services to Chinese and multinational customers.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter